The U.S. Food and Drug Administration (FDA) grants its Breakthrough Therapy designation to new drugs that show promise, to speed up the drugs’ development and review. A new type 1 diabetes drug, vTv Therapeutics’ TTP399, which is being developed as an adjunctive therapy to insulin for type 1 diabetes, has been granted this designation. Read more